Utility of a new bolus-injectable nanoparticle for clinical cancer staging

Mukesh Harisinghani, Robert W. Ross, Alexander R. Guimaraes, Ralph Weissleder

Research output: Contribution to journalArticlepeer-review

81 Scopus citations


BACKGROUND: In this study, we report on the use of a new, bolus-injectable, carboxymethyl dextran-based magnetic nanoparticle (MNP), ferumoxytol, to improve detection in loco-regional lymph nodes by magnetic resonance imaging (MRI). METHODS: This preliminary study was performed as a prospective, single-center, open label pilot study to determine the magnitude of nodal MRI signal changes and to determine the optimal time points for imaging following intravenous (IV) bolus injection of the MNP. The study group consisted of 10 patients, all of whom were diagnosed with prostate cancer before any systemic therapy. RESULTS: All 10 patients had lymph nodes evaluated by histopathology. Of the evaluated 26 lymph nodes, 20 were benign and 6 were malignant. The mean short-axis diameter of benign lymph nodes was 6 mm and the mean short-axis diameter of malignant lymph nodes was 7 mm. Following IV administration, there was a significant change in mean signal-to-noise ratio (SNR) of benign lymph nodes (P < .0001) whereas there was little change in the mean SNR of malignant nodes (P = .1624). No adverse events were encountered. CONCLUSION: Ferumoxytol is safe and, at the appropriate circulation interval, modulates nodal signal intensity, allowing for identification of malignant nodal involvement by MRI.

Original languageEnglish (US)
Pages (from-to)1160-1165
Number of pages6
Issue number12
StatePublished - Dec 2007
Externally publishedYes


  • Ferumoxytol
  • Lymph nodes
  • MRI
  • Nanoparticle
  • Prostate cancer

ASJC Scopus subject areas

  • Cancer Research


Dive into the research topics of 'Utility of a new bolus-injectable nanoparticle for clinical cancer staging'. Together they form a unique fingerprint.

Cite this